Webinar: Medication related osteonecrosis of the jaw (MRONJ)

This webinar aims to assist dentists to understand the patho-physiology of MRONJ and to give analytical instructions regarding the screening of patients at risk, prevention, diagnostic criteria, and management strategies of patients with this condition.

Treatment of osteoporosis or bone metastases with agents, such as bisphosphonates or denosumab, or other agents, such as angiogenesis inhibitors may cause a rare potentially serious condition called Medication-Related Osteonecrosis of the Jaw (MRONJ).

While numerous etiopathogenic mechanisms of this condition have been proposed, the precise mechanism for MRONJ is not yet clearly understood. While in most cases MRONJ manifests as exposed bone in the jaw, unexposed MRONJ has also been identified. Patients report current or previous treatment with bisphosphonates or denosumab, or angiogenesis inhibitors, but no history of radiotherapy to the jaws or obvious metastatic disease of the jaws. Although multidisciplinary treatment strategies have been developed, prevention of MRONJ is of a major importance. 

Main topics addressed

• List of antiresorptive medications
• List of antiangiogenic medications
• Risk profile
• Management

Learning outcomes

• Identifications of osteometabolic patients
• Identicfications of oncologic patients
• News concerning the management of MRONJ